Agenus Inc Total Assets
Agenus Inc total assets. Based on the latest financial reports, Agenus Inc (AGEN) holds total assets worth $172.69 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Agenus Inc stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Agenus Inc (1999–2025)
Total assets of Agenus Inc from 1999 to 2025. This chart illustrates how Agenus Inc's total assets have evolved over time, based on quarterly financial data. See Agenus Inc stock price for real-time trading data and today's change.
Agenus Inc - Asset Composition Analysis
Agenus Inc Total Assets Breakdown (December 2025)
Agenus Inc total assets breakdown as of December 2025. Agenus Inc's total assets of $172.69 Million consist of 58.8% current assets and 41.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.3% |
| Accounts Receivable | $1.83 Million | 0.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.04 Million | 1.3% |
| Goodwill | $24.09 Million | 10.6% |
Asset Composition Trend (1999–2025)
This chart illustrates how Agenus Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore AGEN current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Agenus Inc's current assets represent 58.8% of total assets in 2025, a decrease from 85.2% in 1999.
- Cash Position: Cash and equivalents constituted 1.3% of total assets in 2025, down from 82.9% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 0.0% in 1999.
- Asset Diversification: The largest asset category is goodwill at 10.6% of total assets.
Agenus Inc Competitors by Total Assets
Key competitors of Agenus Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Agenus Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.34 | 0.06 | 2.05 |
| Quick Ratio | 0.34 | 0.06 | 1.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-153.01 Million | $-221.22 Million | $158.27 Million |
Agenus Inc - Advanced Valuation Insights
This section examines the relationship between Agenus Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 218.61 |
| Latest Market Cap to Assets Ratio | 1.32 |
| Asset Growth Rate (YoY) | 0.2% |
| Total Assets | $226.80 Million |
| Market Capitalization | $300.29 Million USD |
Valuation Analysis
Above Book Valuation: The market values Agenus Inc's assets above their book value (1.32x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Agenus Inc's assets grew by 0.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Agenus Inc (1999–2025)
The table below shows the annual total assets of Agenus Inc from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $226.80 Million | +0.23% |
| 2024-12-31 | $226.27 Million | -27.92% |
| 2023-12-31 | $313.91 Million | -24.09% |
| 2022-12-31 | $413.56 Million | -11.25% |
| 2021-12-31 | $465.96 Million | +117.22% |
| 2020-12-31 | $214.51 Million | +38.10% |
| 2019-12-31 | $155.34 Million | +13.88% |
| 2018-12-31 | $136.40 Million | -1.45% |
| 2017-12-31 | $138.40 Million | -11.84% |
| 2016-12-31 | $156.99 Million | -35.19% |
| 2015-12-31 | $242.23 Million | +225.02% |
| 2014-12-31 | $74.53 Million | +113.94% |
| 2013-12-31 | $34.84 Million | +0.47% |
| 2012-12-31 | $34.67 Million | +75.05% |
| 2011-12-31 | $19.81 Million | -35.91% |
| 2010-12-31 | $30.91 Million | -32.63% |
| 2009-12-31 | $45.87 Million | -19.44% |
| 2008-12-31 | $56.95 Million | +27.86% |
| 2007-12-31 | $44.54 Million | -38.95% |
| 2006-12-31 | $72.95 Million | -29.96% |
| 2005-12-31 | $104.15 Million | -21.73% |
| 2004-12-31 | $133.06 Million | -5.01% |
| 2003-12-31 | $140.08 Million | +57.28% |
| 2002-12-31 | $89.06 Million | -4.79% |
| 2001-12-31 | $93.55 Million | -26.90% |
| 2000-12-31 | $127.97 Million | +128.51% |
| 1999-12-31 | $56.00 Million | -- |
About Agenus Inc
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvan… Read more